Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Fluids and Barriers of the CNS
Published in: Fluids and Barriers of the CNS 1/2016

Open Access 01-12-2016 | Research

Amyloid mis-metabolism in idiopathic normal pressure hydrocephalus

Authors: A. Jeppsson, Mikko Höltta, H. Zetterberg, K. Blennow, C. Wikkelsø, Mats Tullberg

Published in: Fluids and Barriers of the CNS | Issue 1/2016

Login to get access

Abstract

Background

Patients with idiopathic normal pressure hydrocephalus (iNPH) have reduced cerebrospinal fluid (CSF) concentrations of amyloid-β (Aβ) and α- and β-cleaved soluble forms of amyloid precursor protein (sAPPα and sAPPβ). The aims of this study were to examine if changes could also be seen in the CSF for secreted metabolites of APP-like protein 1 (APLP1) and to explore the prognostic value of amyloid-related CSF biomarkers, as well as markers of neuronal injury and astroglial activation, as regards to clinical outcome after shunt surgery.

Methods

Twenty patients diagnosed with iNPH, 10 improved and 10 unchanged by shunt surgery, and 20 neurologically healthy controls were included. All patients were examined clinically prior to surgery and at 6-month follow-up after surgery using the iNPH scale. Lumbar puncture was performed pre-operatively. CSF samples were analyzed for neurofilament light (NFL), Aβ isoforms Aβ38, Aβ40 and Aβ42, sAPPα, sAPPβ, APLP1 β-derived peptides APL1β25, APL1β 27 and APL1β 28 and YKL40 by immunochemical methods.

Results

The concentrations of all soluble forms of APP, all Aβ isoforms and APL1β28 were lower, whilst APL1β25 and APL1β27 were higher in the CSF of iNPH patients compared to controls. There was no difference in biomarker concentrations between patients who improved after surgery and those who remained unchanged.

Conclusions

The reduced CSF concentrations of Aβ38, Aβ40, Aβ42, sAPPα and sAPPβ suggest that APP expression could be downregulated in iNPH. In contrast, APLP1 concentration in the CSF seems relatively unchanged. The increase of APL1β25 and APL1β27 in combination with a slight decreased APL1β28 could be caused by more available γ-secretase due to reduced availability of its primary substrate, APP. The data did not support the use of these markers as indicators of shunt responsiveness.
Literature
1.
Hakim S, Adams RD. The special clinical problem of symptomatic hydrocephalus with normal cerebrospinal fluid pressure. Observations on cerebrospinal fluid hydrodynamics. J Neurol Sci. 1965;2:307–27.CrossRefPubMed
2.
Fisher CM. The clinical picture in occult hydrocephalus. Clin Neurosurg. 1977;24:270–84.PubMed
3.
Klinge P, Hellström P, Tans J, Wikkelsø C. One-year outcome in the European multicentre study on iNPH. Acta Neurol Scand. 2012;126:145–53.CrossRefPubMed
4.
Andrén K, Wikkelsø C, Tisell M, Hellström P. Natural course of idiopathic normal pressure hydrocephalus. J Neurol Neurosurg Psychiatry. 2014;85:806–10.CrossRefPubMed
5.
McAllister JP, Williams MA, Walker ML, Kestle JRW, Relkin NR, Anderson AM, et al. An update on research priorities in hydrocephalus: overview of the third National Institutes of Health-sponsored symposium “opportunities for hydrocephalus research: pathways to better outcomes”. J Neurosurg. 2015;123:1427–38.CrossRefPubMed
6.
Jeppsson A, Zetterberg H, Blennow K, Wikkelsø C. Idiopathic normal-pressure hydrocephalus Pathophysiology and diagnosis by CSF biomarkers. Neurology. 2013;80:1385–92.CrossRefPubMed
7.
Miyajima M, Nakajima M, Ogino I, Miyata H, Motoi Y, Arai H. Soluble amyloid precursor protein α in the cerebrospinal fluid as a diagnostic and prognostic biomarker for idiopathic normal pressure hydrocephalus. Eur J Neurol. 2013;20:236–42.CrossRefPubMed
8.
Ågren-Wilsson A, Lekman A, Sjöberg W, Rosengren L, Blennow K, Bergenheim AT, et al. CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus. Acta Neurol Scand. 2007;116:333–9.CrossRefPubMed
9.
Ray B, Reyes PF, Lahiri DK. Biochemical studies in normal pressure hydrocephalus (NPH) patients: change in CSF levels of amyloid precursor protein (APP), amyloid-beta (Aβ) peptide and phospho-tau. J Psychiatr Res. 2011;45:539–47.CrossRefPubMed
10.
Eggert S, Paliga K, Soba P, Evin G, Masters CL, Weidemann A, et al. The proteolytic processing of the amyloid precursor protein gene family members APLP-1 and APLP-2 involves α-, β-, γ-, and ε-Like cleavages: modulation of APLP-1 processing by N-glycosylation. J Biol Chem. 2004;279:18146–56.CrossRefPubMed
11.
Moriya M, Miyajima M, Nakajima M, Ogino I, Arai H. Impact of cerebrospinal fluid shunting for idiopathic normal pressure hydrocephalus on the amyloid cascade. PLoS One. 2015;10(3):e0119973.CrossRefPubMedPubMedCentral
12.
Jacobsen KT, Iverfeldt K. Amyloid precursor protein and its homologues: a family of proteolysis-dependent receptors. Cell Mol Life Sci. 2009;66:2299–318.CrossRefPubMed
13.
Yanagida K, Okochi M, Tagami S, Nakayama T, Kodama TS, Nishitomi K, et al. The 28-amino acid form of an APLPl-derived Aβ-like peptide is a surrogate marker for Aβ42 production in the central nervous system. EMBO Mol Med. 2009;1:223–35.CrossRefPubMedPubMedCentral
14.
Tagami S, Okochi M, Yanagida K, Kodama T, Arai T, Kuwano R, et al. Relative ratio and level of amyloid-β 42 surrogate in cerebrospinal fluid of familial alzheimer disease patients with presenilin 1 mutations. Neurodegener Dis. 2014;13:166–70.CrossRefPubMed
15.
Laiterä T, Sarajärvi T, Haapasalo A, Puli L, Kauppinen T, Mäkinen P, et al. Increased γ-secretase activity in idiopathic normal pressure hydrocephalus patients with β-amyloid pathology. PLoS One. 2014;9(4):e93717.CrossRefPubMedPubMedCentral
16.
Relkin N, Marmarou A, Klinge P, Bergsneider M, Black PM. Diagnosing idiopathic normal-pressure hydrocephalus. Neurosurgery. 2005;57:S4–16 (discussion ii–v).PubMed
17.
Hellström P, Klinge P, Tans J, Wikkelsø C. A new scale for assessment of severity and outcome in iNPH. Acta Neurol Scand. 2012;126:229–37.CrossRefPubMed
18.
Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjögren M, et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke. 2001;32:1318–22.CrossRefPubMed
19.
Tarnaris A, Toma AK, Pullen E, Chapman MD, Petzold A, Cipolotti L, et al. Cognitive, biochemical, and imaging profile of patients suffering from idiopathic normal pressure hydrocephalus. Alzheimers Dement. 2011;7:501–8.CrossRefPubMed
20.
Lins H, Wichart I, Bancher C, Wallesch CW, Jellinger KA, Rösier N. Immunoreactivities of amyloid β peptide(1-42) and total τ protein in lumbar cerebrospinal fluid of patients with normal pressure hydrocephalus. J Neural Transm. 2004;111:273–80.CrossRefPubMed
21.
Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, et al. Improved discrimination of AD patients using β-amyloid (1–42) and tau levels in CSF. Neurology. 1999;52:1555–62.CrossRefPubMed
22.
Kapaki EN, Paraskevas GP, Tzerakis NG, Sfagos C, Seretis A, Kararizou E, et al. Cerebrospinal fluid tau, phospho-tau181 and β-amyloid 1–42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer’s disease. Eur J Neurol. 2007;14:168–73.CrossRefPubMed
23.
24.
Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M, et al. Sleep drives metabolite clearance from the adult brain. Science. 2013;342:373–7.CrossRefPubMed
25.
Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Sci Transl Med. 2012;4:147ra11.CrossRef
26.
Shibata M, Yamada S, Ram Kumar S, Calero M, Bading J, Frangione B, et al. Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest. 2000;106:1489–99.CrossRefPubMedPubMedCentral
27.
Kress BT, Iliff JJ, Xia M, Wang M, Wei HS, Zeppenfeld D, et al. Impairment of paravascular clearance pathways in the aging brain. Ann Neurol. 2014;76:845–61.CrossRefPubMedPubMedCentral
28.
Hashimoto M, Ishikawa M, Mori E, Kuwana N. Diagnosis of idiopathic normal pressure hydrocephalus is supported by MRI-based scheme: a prospective cohort study. Cerebrospinal Fluid Res. 2010;7:1.CrossRef
29.
Larsson A, Arlig A, Bergh AC, Bilting M, Jacobsson L, Stephensen H, et al. Quantitative SPECT cisternography in normal pressure hydrocephalus. Acta Neurol Scand. 1994;90:190–6.CrossRefPubMed
30.
Laiterä T, Kurki MI, Pursiheimo JP, Zetterberg H, Helisalmi S, Rauramaa T, et al. The expression of transthyretin and amyloid-β protein precursor is altered in the brain of idiopathic normal pressure hydrocephalus patients. J Alzheimers Dis. 2015;48:959–68.CrossRefPubMed
31.
Tullberg M, Jensen C, Ekholm S, Wikkelsø C. Normal pressure hydrocephalus: vascular white matter changes on MR images must not exclude patients from shunt surgery. AJNR Am J Neuroradiol. 2001;22:1665–73.PubMed
32.
Sjödin S, Andersson KKA, Mercken M, Zetterberg H, Borghys H, Blennow K, et al. APLP1 as a cerebrospinal fluid biomarker for γ-secretase modulator treatment. Alzheimers Res Ther. 2015;7:1.CrossRef
33.
Portelius E, Price E, Brinkmalm G, Stiteler M, Olsson M, Persson R, et al. A novel pathway for amyloid precursor protein processing. Neurobiol Aging. 2011;32:1090–8.CrossRefPubMed
34.
35.
Portelius E, Hölttä M, Soininen H, Bjerke M, Zetterberg H, Westerlund A, et al. Altered cerebrospinal fluid levels of amyloid β and amyloid precursor-like protein 1 peptides in Down’s syndrome. Neuromol Med. 2014;16:510–6.CrossRef
36.
Blennow K, Hampel H. CSF markers for incipient Alzheimer’s disease. Lancet Neurol. 2003;2:605–13.CrossRefPubMed
37.
Metadata
Title
Amyloid mis-metabolism in idiopathic normal pressure hydrocephalus
Authors
A. Jeppsson
Mikko Höltta
H. Zetterberg
K. Blennow
C. Wikkelsø
Mats Tullberg
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Fluids and Barriers of the CNS / Issue 1/2016
Electronic ISSN: 2045-8118
DOI
https://doi.org/10.1186/s12987-016-0037-y

Other articles of this Issue 1/2016

Fluids and Barriers of the CNS 1/2016 Go to the issue

Research

Misleading early blood volume changes obtained using ferumoxytol-based magnetic resonance imaging perfusion in high grade glial neoplasms treated with bevacizumab

Research

Modeling immune functions of the mouse blood–cerebrospinal fluid barrier in vitro: primary rather than immortalized mouse choroid plexus epithelial cells are suited to study immune cell migration across this brain barrier

Research

Diffusion tensor imaging with direct cytopathological validation: characterisation of decorin treatment in experimental juvenile communicating hydrocephalus

Review

The restorative role of annexin A1 at the blood–brain barrier

Research

A comparison between the pathophysiology of multiple sclerosis and normal pressure hydrocephalus: is pulse wave encephalopathy a component of MS?

Research

Magnesium sulfate treatment for juvenile ferrets following induction of hydrocephalus with kaolin